APPL
Aptus Pharma financials
- Market cap
- ₹317 Cr
Quarterly results
| Line item | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|
| Revenue | 10 | 15 | 14 | 32 |
| EBITDA | 2 | 3 | 3 | 5 |
| Net profit | 1 | 2 | 2 | 3 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +901.5% 1Y
1Y: ₹33.94 on 30 Sept 2025 → ₹339.9. High ₹340 (9 Sept 2026), low ₹33.2 (3 Oct 2025).
Balance sheet
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹0 Cr | ₹7 Cr | ₹7 Cr |
| Reserves | ₹1 Cr | ₹1 Cr | ₹15 Cr | ₹16 Cr |
| Borrowings | ₹2 Cr | ₹5 Cr | ₹8 Cr | ₹7 Cr |
| Other liabilities | ₹3 Cr | ₹3 Cr | ₹10 Cr | ₹13 Cr |
| Total liabilities | ₹6 Cr | ₹10 Cr | ₹40 Cr | ₹44 Cr |
| Fixed assets | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹6 Cr | ₹9 Cr | ₹38 Cr | ₹41 Cr |
| Total assets | ₹6 Cr | ₹10 Cr | ₹40 Cr | ₹44 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Sep 2025, the public added +12.82 pp while FIIs trimmed −10.03 pp. The shareholder count grew 222% to 686.
- Promoters
- 72.9%
- Public
- 27.1%
Since Sep 2025
- Public +12.82 pp
- FIIs −10.03 pp
- DIIs −2.80 pp
How it drifted, 4 quarters
Over this window the public went from 14.3% to 27.1% — +12.8 pp.
Ownership split by quarter, oldest first. Sep '25: Promoters 72.9%, FIIs 10.0%, DIIs 2.8%, Public 14.3%.Dec '25: Promoters 72.9%, Public 27.1%.Mar '26: Promoters 72.9%, Public 27.1%.Jun '26: Promoters 72.9%, Public 27.1%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Riddhish Natwarlal Tanna +0.26 pp 8.64% held
- Kripaliben Mayank Thakker +0.26 pp 8.64% held
- Milly Chetan Lalseta +0.26 pp 8.64% held
- Kunjal Piyushbhai Unadkat +0.26 pp 8.64% held
- Gaurang Rameshchandra Thakker +0.26 pp 8.64% held
- Ghanshyam Vinubhai Pansuriya +0.21 pp 5.31% held
- Tejash Maheshchandra Hathi +0.14 pp 11.44% held
- Kapil Hasmukhbhai Chandarana +0.14 pp 11.44% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Aptus Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Tejash Maheshchandra Hathi | 11.44% | +0.14 pp |
| Kapil Hasmukhbhai Chandarana | 11.44% | +0.14 pp |
| Riddhish Natwarlal Tanna | 8.64% | +0.26 pp |
| Kripaliben Mayank Thakker | 8.64% | +0.26 pp |
| Milly Chetan Lalseta | 8.64% | +0.26 pp |
| Kunjal Piyushbhai Unadkat | 8.64% | +0.26 pp |
| Gaurang Rameshchandra Thakker | 8.64% | +0.26 pp |
| Ghanshyam Vinubhai Pansuriya | 5.31% | +0.21 pp |
| Chatrabhuj Vallabhbhai Butani | 1.47% | −1.81 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Aptus Pharma Limited
Guides on how to read this kind of business and the numbers that matter.